articleTop 1% cited

A 17-gene Assay to Predict Prostate Cancer Aggressiveness in the Context of Gleason Grade Heterogeneity, Tumor Multifocality, and Biopsy Undersampling

European Urology · 2014 · Vol. 66(3) · pp. 550–560

Eric A. Klein✉(Cleveland Clinic)Matthew R. Cooperberg(UCSF Helen Diller Family Comprehensive Cancer Center)Cristina Magi‐Galluzzi(Cleveland Clinic)Jeffry Simko(UCSF Helen Diller Family Comprehensive Cancer Center)Sara M. Falzarano(Cleveland Clinic)Tara Maddala(Genomic Health (United States))June M. Chan(University of California, San Francisco)Jianbo Li(Genomic Health (United States))Janet E. Cowan(UCSF Helen Diller Family Comprehensive Cancer Center)Athanasios C. Tsiatis(Genomic Health (United States))Diana B. Cherbavaz(Genomic Health (United States))Robert J. Pelham(Genomic Health (United States))Imelda Tenggara-Hunter(University of California, San Francisco)Frederick L. Baehner(Genomic Health (United States))Dejan Knezevic(Genomic Health (United States))Phillip G. Febbo(Genomic Health (United States))Steven Shak(Genomic Health (United States))Michael W. Kattan(Cleveland Clinic)Mark Lee(Genomic Health (United States))Peter R. Carroll✉(University of California, San Francisco)

View via DOI Publisher page

Prostate Cancer Treatment and Research Prostate Cancer Diagnosis and Treatment Molecular Biology Techniques and ApplicationsMedicineProstate cancerProstatectomyBiopsyProstate biopsyProstate-specific antigenProportional hazards modelOncologyBiochemical recurrenceInternal medicine

MeSH terms

AgedAlgorithmsHumansMaleMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingProstatectomyProstatic NeoplasmsGene ExpressionRisk AssessmentTranscriptomeNeoplasm GradingEndoscopic Ultrasound-Guided Fine Needle Aspiration